Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Behçet's disease].

Bertrand Wechsler1, Lê Thi Huong Du-Boutin, Zahir Amoura

  • 1Service de médecine interne, groupe hospitalier La Pitié-La Salpêtrière, 75651 Paris Cedex 13. bertrand.wechsler@psl.aphp.fr

La Revue Du Praticien
|April 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of patients with isolated cutaneous lupus erythematosus versus systemic lupus erythematosus with cutaneous lupus erythematosus as the sole clinical feature: A monocentric study of 149 patients.

Journal of the American Academy of Dermatology·2024
Same author

Prognostic value of hypermetabolic bone sarcoidosis observed by 18F-fluorodeoxyglucose positron emission tomography.

Rheumatology (Oxford, England)·2024
Same author

Low plasma belimumab levels as an indicator of poor adherence to belimumab in patients with systemic lupus erythematosus.

Annals of the rheumatic diseases·2023
Same author

Higher Levels of SARS-CoV-2 Genetic Variation in Immunocompromised Patients: A Retrospective Case-Control Study.

The Journal of infectious diseases·2023
Same author

Systemic lupus erythematosus and glucocorticoids: A never-ending story?

Best practice & research. Clinical rheumatology·2023
Same author

Heart and systemic sclerosis-findings from a national cohort study.

Rheumatology (Oxford, England)·2023
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Behçet's disease is a rare vasculitis requiring diagnosis via mucocutaneous symptoms. While treatments manage symptoms, severe cases may need immunosuppressants or biologics like infliximab for better outcomes.

Area of Science:

  • Rheumatology
  • Immunology
  • Vascular Medicine

Context:

  • Behçet's disease is a complex systemic vasculitis with an unknown etiology.
  • Diagnosis relies heavily on characteristic mucocutaneous manifestations.
  • Potential for severe ocular, neurological, and arterial involvement necessitates prompt management.

Purpose:

  • To summarize the key diagnostic criteria, clinical manifestations, and therapeutic strategies for Behçet's disease.
  • To highlight the role of conventional and advanced treatments in managing this chronic inflammatory condition.
  • To emphasize the importance of patient education and adherence for improving prognosis.

Summary:

  • Behçet's disease is characterized by mucocutaneous lesions, with ocular, neurological, and arterial involvement posing significant risks.

Related Experiment Videos

  • Symptomatic treatments include steroids, colchicine, and antiplatelet agents.
  • Immunosuppressive therapy, alpha interferon, and infliximab are reserved for severe or refractory cases.

    • Impact:

    • Understanding Behçet's disease facilitates timely diagnosis and appropriate management, potentially preventing severe organ damage.
    • Effective treatment strategies can mitigate the debilitating effects of the disease, improving patient quality of life.
    • Highlighting the need for patient education underscores its role in managing chronic illness and enhancing long-term outcomes.